NDAORALCAPSULEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
NALFON (fenoprofen calcium) by Teva is analgesic, anti-inflammatory, and antipyretic properties. Approved for rheumatoid arthritis. First approved in 1976.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NALFON (fenoprofen calcium) is an oral NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis, providing analgesic, anti-inflammatory, and antipyretic effects. It is indicated for rheumatoid arthritis and works by decreasing prostaglandins in peripheral tissues to reduce inflammation and pain. The drug has been on the market since 1976 and is now approaching loss of exclusivity.
$0.023BPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with minimal spending ($23K in Part D claims), the NALFON brand team is likely small and focused on defending share against generic and competitive erosion rather than growth.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of FENOPROFEN CALCIUM, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Fenoprofen is a potent inhibitor of prostaglandin synthesis in vitro.…
Indications (1)
Career Relevance
Worked on NALFON at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.